Despite the considerable efficacy observed when targeting a dispensable lineage antigen,
such as CD19 in B cell acute lymphoblastic leukaemia,, the broader applicability of adoptive …

Antigen-directed immunotherapies for acute myeloid leukemia (AML), such as chimeric
antigen receptor T cells (CAR-Ts) or antibody-drug conjugates (ADCs), are associated with …

Transplantation of hematopoietic cells from a healthy individual (allogeneic hematopoietic
cell transplantation (allo-HCT)) demonstrates that adoptive immunotherapy can cure blood …

Adoptive immunotherapy using chimeric antigen receptor (CAR) expressing T cells targeting
the CD19 B lineage receptor has demonstrated marked success in relapsed pre-B-cell acute …

The absence of cancer-restricted surface markers is a major impediment to antigen-specific
immunotherapy using chimeric antigen receptor (CAR) T cells. For example, targeting the …

Targeted eradication of transformed or otherwise dysregulated cells using monoclonal
antibodies (mAb), antibody–drug conjugates (ADC), T cell engagers (TCE), or chimeric …

Recent advances in antibody technology to harness T cells for cancer immunotherapy,
particularly in the difficult-to-treat setting of relapsed/refractory acute lymphoblastic leukemia …

Many patients with acute myeloid leukemia (AML) are incurable with chemotherapy and may
benefit from novel approaches. One such approach involves the transfer of T cells …

Adoptive transfer of receptor-engineered T cells has produced impressive results in treating
patients with B cell leukemias and lymphomas. This success has captured public …

The genetic modification of autologous T cells with chimeric antigen receptors (CARs)
represents a breakthrough for gene engineering as a cancer therapy for hematologic …